Tengfei Zhang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Density matters for better battery material performance

Zinc cheap, abundant, environmentally friendly may be the answer to better batteries, but there’s a major problem: Aqueous zinc ion batteries (AZIBs) cannot match lithium-ion batteries in term .

Jun zhouCuiping hanMeilin liQingming liuTengfei zhangSenlin liFanbin zengShenzhen institute of advanced technologyEnergy materialsChinese academy of sciencesInstitute of technologyCarbon neutralityShenzhen instituteAdvanced technologyChinese academyAqueous zinc ion batteries

Harnessing the Potential of High-Performance Organic Cathodes

Zinc, which is inexpensive, abundant, and ecologically friendly, could be the answer to better batteries, but there is a huge issue: In terms of power output, aqueous zinc ion batteries (AZIBs) cannot compete with lithium-ion batteries. To see what electrode material composition could bring AZIBs up to par, a Chinese research team created two organic frameworks with the same elements but arranged differently.

Fanbin zengTengfei zhangMeilin liCuiping hanSkyla bailyQingming liuJun zhouSenlin liResearch foundationVehicle battery technology industryVehicle battery technologyChinese academy of sciencesChina postdoctoral science foundationEnergy materialsTsinghua universityStudy co

Density Key to Enhanced Battery Performance, Study Reveals

Density Key to Enhanced Battery Performance, Study Reveals
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Jun zhouCuiping hanMeilin liTengfei zhangSenlin liFanbin zengQingming liuShenzhen institute of advanced technologyTowngas energy academyTsinghua universityProduction servicesOutstanding youth basic research project of shenzhenNational natural science foundation of chinaEnergy materialsChinese academy of sciencesResearch foundation

Gulf Resources Announces Management Changes

Gulf Resources Announces Management Changes
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Amin yangTengfei zhangXiaobin liuLiu xiaobinCorporate governance committeeExchange commissionShouguang city haoyuan chemical company limitedDaying county haoyuan chemical company limitedShouguang yuxin chemical industry coCompany onCompensation committeeShouguang hengde salt industry coSecurities exchangeGulf resources incAnnual meetingChief executive officer

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

Objective To assess the efficacy and safety of pyrotinib (an irreversible pan-HER (human epidermal growth factor receptor) inhibitor), trastuzumab, and docetaxel compared with placebo, trastuzumab, and docetaxel for untreated HER2 positive metastatic breast cancer. Design Randomised, double blind, placebo controlled, multicentre, phase 3 trial. Setting 40 centres in China between 6 May 2019 and 17 January 2022. Participants 590 female patients (median age 52 (interquartile range 46-58) years) with untreated HER2 positive metastatic breast cancer. Interventions Eligible patients were randomised 1:1 to receive either oral pyrotinib (400 mg once daily) or placebo, both combined with intravenous trastuzumab (8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2) on day 1 of each 21 day cycle. Randomisation was stratified by treatment history of trastuzumab in the (neo)adjuvant setting and hormone receptor status. Patients, investigators, and the sponsor’s study

Eteläuomen läiPconclusions pyrotinibJiaman lin hengruiTengfei zhangDemets obrien flemingKaijing zhao hengruiEastern cooperative oncology groupHuman genetic resource administration of chinaDrug administrationJiangsu hengrui pharmaceuticalsChina national medical products administrationInnovation fund for medical sciencesResponse evaluation criteriaSolid tumorsNational cancer instituteCommon terminology criteria